edited by David A. Gewirtz, Shawn E. Holt, Steven Grant
EDITION STATEMENT
Edition Statement
2nd ed
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Totowa, N.J. :
Name of Publisher, Distributor, etc.
Humana Press,
Date of Publication, Distribution, etc.
2007
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
xvii, 599 p. :
Other Physical Details
ill. ;
Dimensions
26 cm
SERIES
Series Title
Cancer drug discovery and development
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index
CONTENTS NOTE
Text of Note
The intrinsic pathway of apoptosis. -- The extrinsic pathway of apoptosis. -- Evaluating the importance of apoptosis and other determinants of cell death and survival. -- Mitotic catastrophe. -- Autophagy and autophagic cell death. -- Regulation and function of detachment-induced cell death (anoikis) in cancer progression and metastasis. -- Structure and function of the telomere. -- Overview of senescence. -- Contributions of telomerase to tumorigenesis. -- The role of telomeres in genomic instability. -- Overview of the DNA damage checkpoint: ATM and ATR. -- Interactions between myc- and cyclin-dependent kinase inhibitors in cancer. -- Interplay between [gamma]H2AX and 53BP1 pathways in DNA double-strand break repair response. -- DNA-dependent protein kinase in repair, apoptosis, telomere maintenance, and chemotherapy. -- Resistance/signaling pathways. -- Ceramide and multidrug resistance. -- Chemo- and radiosensitization through inhibition of PI3K/Akt signaling. -- The advancement of epidermal growth factor receptor inhibitors in cancer therapy. -- Antimetabolites. -- Topoisomerase I poisons and apoptotic topoisomerase I-DNA complexes. -- Perturbations of cellular functions by topoisomerase II inhibitors: all roads lead to cell death? -- The significance of poly-targeting in apoptosis induction by alkylating agents and platinum drugs. -- Contributions of apoptosis and senescence to cytotoxicity produced by microtubule-stabilizing agents. -- Tyrosine kinase inhibitors. -- Monoclonal antibodies in lymphomas. -- Role of apoptosis in anti-angiogenic cancer therapies. -- Photodynamic therapy-induced apoptosis. -- Modulation of TRAIL signaling for cancer therapy